Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis

Biotech Revenue Trends: Regeneron vs. Ligand (2014-2023)

__timestampLigand Pharmaceuticals IncorporatedRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014645380002819557000
Thursday, January 1, 2015719140004103728000
Friday, January 1, 20161089730004860427000
Sunday, January 1, 20171411020005872227000
Monday, January 1, 20182514530006710800000
Tuesday, January 1, 20191202820007863400000
Wednesday, January 1, 20201864190008497100000
Friday, January 1, 202127713300016071700000
Saturday, January 1, 202219624500012172900000
Sunday, January 1, 202313131400013117200000
Monday, January 1, 202414202000000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have showcased contrasting revenue trajectories. Regeneron, a leader in the biotech industry, has seen its revenue skyrocket by over 360% from 2014 to 2023, peaking in 2021 with a remarkable 1.6 billion dollars. This growth reflects its robust pipeline and successful product launches.

Conversely, Ligand Pharmaceuticals has experienced a more modest revenue increase of approximately 100% over the same period. Despite a peak in 2021, Ligand's revenue has shown fluctuations, highlighting the challenges smaller biotech firms face in maintaining consistent growth. This analysis underscores the diverse strategies and market conditions influencing biotech companies today.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025